Pharmacotherapy of Nonalcoholic Fatty Liver Disease (MASLD)

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorAyyoub, Marnih Eyad Issa
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentSzentmiklósi, József
dc.contributor.opponentHalasi, Barbara Dóra
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.date.accessioned2025-07-01T13:50:16Z
dc.date.available2025-07-01T13:50:16Z
dc.date.created2025-05-12
dc.description.abstractMetabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), represents the most prevalent chronic liver disorder globally, affecting nearly 30% of adults. MASLD encompasses a spectrum of hepatic abnormalities, ranging from benign fat accumulation (steatosis) to more advanced stages such as metabolic dysfunction-associated steatohepatitis (MASH), progressive fibrosis, cirrhosis, and even hepatocellular carcinoma. The pathogenesis of MASLD is multifactorial, shaped by metabolic imbalances, genetic predispositions, and environmental influences. Major risk factors include insulin resistance, obesity, type 2 diabetes mellitus, and dyslipidemia. Diagnosis is commonly achieved through imaging studies, non-invasive biomarkers, and, in some cases, liver biopsy. While lifestyle modification remains the first-line intervention, pharmacologic treatment is indicated in individuals with MASH or significant fibrosis. Recent therapeutic advances include agents such as GLP-1 receptor agonists, SGLT2 inhibitors, PPAR agonists, and resmetirom—a thyroid hormone receptor-β agonist that has recently gained approval. Additional compounds targeting hepatic inflammation, fibrosis, and gut microbiota are under clinical investigation. Innovative approaches like combination regimens and individualized therapy are being explored to accommodate the heterogeneous nature of the disease and improve outcomes. Ongoing research efforts are focused on refining diagnostic tools, enhancing patient stratification, and expanding the therapeutic arsenal for MASLD.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent62
dc.identifier.urihttps://hdl.handle.net/2437/395299
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectpharmacotherapy
dc.subjectnonalcoholic fatty liver disease
dc.subjectMASLD
dc.subjectMetabolic dysfunction-associated steatotic liver disease
dc.subject.dspaceMedicine
dc.titlePharmacotherapy of Nonalcoholic Fatty Liver Disease (MASLD)
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
THESIS MARNIH EYAD ISSA AYYOUB.pdf
Méret:
1.13 MB
Formátum:
Adobe Portable Document Format
Leírás:
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), represents the most prevalent chronic liver disorder globally, affecting nearly 30% of adults. MASLD encompasses a spectrum of hepatic abnormalities, ranging from benign fat accumulation (steatosis) to more advanced stages such as metabolic dysfunction-associated steatohepatitis (MASH), progressive fibrosis, cirrhosis, and even hepatocellular carcinoma. The pathogenesis of MASLD is multifactorial, shaped by metabolic imbalances, genetic predispositions, and environmental influences. Major risk factors include insulin resistance, obesity, type 2 diabetes mellitus, and dyslipidemia. Diagnosis is commonly achieved through imaging studies, non-invasive biomarkers, and, in some cases, liver biopsy. While lifestyle modification remains the first-line intervention, pharmacologic treatment is indicated in individuals with MASH or significant fibrosis. Recent therapeutic advances include agents such as GLP-1 receptor agonists, SGLT2 inhibitors, PPAR agonists, and resmetirom—a thyroid hormone receptor-β agonist that has recently gained approval. Additional compounds targeting hepatic inflammation, fibrosis, and gut microbiota are under clinical investigation. Innovative approaches like combination regimens and individualized therapy are being explored to accommodate the heterogeneous nature of the disease and improve outcomes. Ongoing research efforts are focused on refining diagnostic tools, enhancing patient stratification, and expanding the therapeutic arsenal for MASLD.
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)